Armata Pharmaceuticals (ARMP) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Armata Pharmaceuticals (ARMP) over the past year, gaining 24.5% versus a gain of 19.9%. Over five years, ARMP leads with a +11.9% price change compared with -66.4% for CRDL. Cardiol Therapeutics is the larger company by market cap ($158.0 million vs $143.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | CRDL |
|---|---|---|
| Share price | $3.86 | $1.30 |
| Market cap | $143.52M | $157.97M |
| 1-day change | +1.31% | -1.52% |
| YTD return | -38.54% | +38.36% |
| 1-year return | +19.88% | +24.53% |
| 5-year return | +11.88% | -66.41% |
| EPS (TTM) | $-5.29 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $2.34 |
| 52-week low | $3.14 | $0.88 |
| Distance from 52-week high | -76.38% | -44.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +353.37% | +543.08% |
| Average volume | 208.13K | 1.44M |
| Shares outstanding | 37.18M | 121.51M |
| Employees | 61 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
ARMP vs CRDL FAQ
Which is bigger, Armata Pharmaceuticals or Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $157.97M compared with $143.52M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or CRDL?
CRDL returned +24.53% over the past 12 months, compared with +19.88% for ARMP (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Cardiol Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.